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1 Introduction
Glycosaminoglycans (GAGs) are distinct from other sugars/oligosaccharides in that they are 
polymers of disaccharide units (Figure 1) composed of an amino sugar, N-acetylglucosamine 
(GlcNAc), or N-acetylgalactosamine (GalNAc), and uronic acid, glucuronic acid (GlcUA), or iduronic 
acid (IdUA). The exception is keratan sulfate (KS) in which the uronic acid is replaced by the neutral 
sugar galactose. Initially, GAGs were thought to be just part of an extracellular glue or ground sub-
stance that held tissues together and provided a liquid-like space between cells for the transport of 
nutrients. However, research using new technologies and techniques over the last two decades has 
revealed that the effects of GAGs on cells are more dynamic than previously thought. In addition to 
their structural roles, GAGs are fundamentally important as modifiers of cell behaviors that range 
from leukocyte recruitment during inflammation to the complex signaling events that help cancer 
cells survive during homing and metastasis. Cellular behaviors and responses depend in part on 
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chain length of the GAG as well as GAG-sugar modifications such as sulfation and acetylation. Lon-
ger GAGs tend to be part of the extracellular matrix (ECM) in which long cable-like structures and 
networks may support tissue structure through cross-linking with other ECM components. Shorter 
GAGs or small oligosaccharides of less than 30-50 sugars may interact with cellular receptors to pro-
mote cell signaling involving antiapoptosis or immunostimulation [1]. 
There are four classes of GAGs (Figure 1): Chondroitin (Chon) sulfate (CS) A through E, hepa-
rin (HP) and heparan sulfate (HS), KS, and hyaluronan (HA). CS is a polymer of the disaccharide 
GlcUA-β1, 3-GalNAc-β1, 4 that can be sulfated at one or more positions: GalNAc-4 (type A), Gal-
NAc-4 (type B), GalNAc-6 (type C), GalNAc-6, GlcUA-2 (type D), and GalNAc-4, 6 (type E). CS-B, 
which is now called dermatan sulfate (DS), is an unusual CS family member in which iduronic acid 
substitutes for some, but not all, glucuronic acid (as in HP and HS) and GlcUA is in an alpha-1, 3 
linkage with GlcNAc. HP and HS are polymers of the disaccharide β1, 4-GlcUA-β1, 4-GlcNAc, in 
which some of the glucuronic acid is converted to iduronic acid. HS differs from HP in that the N-
acetylglucosamine is de-N-acetylated and N-sulfated at position 2. HP is typically more highly sul-
fated than HS and is primarily found in mast cells of the immune system. In contrast, HS is ubiq-
uitous throughout the body and its sugars are highly sulfated in patches along the chain, allowing 
differing ligands to bind to regions of higher or lower anionic charge density. Although KS does not 
Figure 1. Schematic structures of the glycosaminoglycans. The GAGs are primarily polymers of disaccharide units 
containing the indicated amino and acidic sugars. Standard symbols for the sugar residues are used as defined by the 
Consortium for Functional Glycomics at  http://grtc.ucsd.edu/essentials.html . All GAGs, with the exception of HA, 
are covalently linked to a variety of the ~40 known core proteins. The GAGs are attached via Ser residues, except for 
KS, which can also be linked via Thr or, less commonly, Asn residues. The arrows indicate that the repeating disac-
charides continue to create larger polysaccharide chains. 
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contain uronic acid, it is grouped with the family of GAGs because of its repeating disaccharide con-
taining GlcNAc. It is assembled on a core protein with either an O-linkage to serine (Ser) or threonine 
(Thr) or an N-linkage to asparagine (Asn) [2]. KS is a major component of lumican and keratocan, 
proteoglycans that are important in the clarity of corneal matrix [3] as well as aggrecan, a structural 
molecule in cartilage and during brain development [4]. 
Unlike the other GAGs, HA is a “free” polysaccharide that is not assembled covalently onto a pro-
teoglycan core protein in the normal biosynthetic organelles (Golgi and ER), but is often bound to 
proteins after its extrusion from the plasma membrane by HA synthase. After it is released by the 
synthase, HA is never sulfated, de-N-acetylated, or modified in any way (except by II as described 
below). All of the GAGs, except HA and some KS chains (as noted above), are attached to and assem-
bled as O-linked glycans on proteoglycan core proteins and are sulfated to various degrees. CS, HP, 
and HS are attached to proteoglycans via Ser, or sometimes Thr residues, and their assembly starts 
with the common tetrasaccharide: GlcUA(β1, 3)Gal(β1, 3)Gal(β1, 4)Xyl(β1)→Ser. 
CS, HP, and HS often act as concomitant molecular signatures for their respective proteoglycans. 
Receptors or binding proteins for the GAGs can be grouped into three different classes. Receptors in 
the first class are soluble proteins that are ECM organizers, such as versican, aggrecan, and neuro-
can. The second class of receptors (e.g., CD44, RHAMM, and TSG6) is associated with cell-mediated 
processes stimulated by GAGs such as inflammation and cellular motility. The third class of recep-
tors (e.g., CD44, HARE/Stabilin-2) is involved in GAG scavenging and turnover and is responsible for 
proper homeostasis of GAG levels in the plasma, tissues, and lymphatic fluids (Figure 2). CD44 is in 
two classes due its functional diversity. 
 
2 Tumor Necrosis Factor-Stimulated Gene 6 
Tumor necrosis factor-stimulated gene 6 (TSG-6), which was formerly named tumor necrosis fac-
tor-induced protein-6 (TNFIP6), is a multi-GAG-binding protein that is secreted during inflamma-
tion in response to chemokines such as IL-1β, TNF, and PGE2. TSG-6 is a serum protein with little or 
no expression under normal conditions, but is quickly secreted in response to inflammatory triggers, 
e.g., during ovulation and arthritis. This 35 kDa protein contains one CUB domain (complement pro-
tein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenic protein), and 
one Link domain and binds a variety of GAGs, including HA [5], CS-A [6], Hep/HS [7], and DS 
[8]. In addition to binding these GAGs, TSG-6 downregulates the inflammatory process by binding 
Figure 2. HA-binding receptors/proteins. The domain organizations of the five HA-binding receptors or proteins dis-
cussed in this chapter are illustrated. The arrow indicates the proteolytic cleavage of the 315 kDa HARE to produce the 
smaller 190 kDa HARE isoform. Except for TSG-6, each colored segment represents exons encoding the indicated type 
of protein domain that is translated from the human gene. The colored segments for TSG-6 represent protein domains. 
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to multiple proteins, such as the G1 domain of aggrecan [9], interalpha-(trypsin)-inhibitor (II) [10], 
pre-alpha-(trypsin)-inhibitor (PI) [11], pentraxin-3 [12], and thrombospondin-1 (TSP-1) [13]. 
The role of HA in inflammatory processes such as wound healing and ovulation is well known. 
Ovulation begins when ovarian cells respond to a spike in luteinizing hormone (LH), which initiates 
a signaling cascade involving cAMP and PGE2 mediators [14]. Granulosa and cumulus cells of the 
oocyte respond to these signal mediators by initiating transcription of a host of genes, one of which 
is TSG-6 [15-17]. TSG-6 also promotes cervical ripening by human cervical smooth muscle cells [18]. 
TSG-6 may be part of a network of factors that promote fertility by remodeling the ECM of the cumu-
lus cell-oocyte complex, a matrix rich in HA [19]. TSG-6 knockout mice are subfertile or completely 
infertile [20]. Upregulation of TSG-6 is also most prominent in areas of chronic inflammation, such as 
the inflamed synovial tissues of rheumatoid arthritis patients [21] and the smooth muscles of the bro-
chia in asthmatic patients [22]. 
2.1 TSG-6 and HA 
II is a unique proteoglycan in which the bikunin moiety, containing two Kunitz domains with an-
tiprotease activity, is covalently linked to two protein heavy chains (HC1 and HC2) via its CS-A chain 
(Figure 3). CS-A is connected to bikunin by the standard GlcUAGalGalXyl-protein linkage at Ser-10. 
The C-terminal Asp648 alpha-carboxyl of each HC is esterified to the C-6 hydroxyl of an internal Gal-
NAc of the CS-A chain [23]. During the inflammatory process, TSG-6 interacts with the HCs of II and 
mediates a reaction in which TSG-6 displaces CS-A and becomes attached to the C-terminal aspartic 
acid of HC1 or HC2 [24, 25]. This reaction promotes transesterification of the HC from II, giving rise 
to two intermediate complexes, TSG-6-HC1 or TSG-6-HC2, in addition to the remaining substrate bi-
Figure 3. HA modification by the heavy chain of inter--trypsin inhibitor. II is a three-member proteoglycan that 
contains two protein heavy chains (HC in boxes), the metalloprotease inhibitor bikunin (B in the circles), and a single 
CS-A chain (solid line). The two HC chains are linked to CS-A by ester linkages at their C-terminal aspartate residues. 
The Cub (C in gray boxes) and Link (L in white box) domains are indicated for TSG-6. TSG-6 acts as a catalyst that 
transfers one of the heavy chains from II to HA (alternating squares and diamonds as in Figure 1) in two steps via 
transesterification reactions. The first reaction results in transfer of one HC chain from II to TSG-6, forming a cova-
lent linkage between the HC C-terminal Asp and TSG-6. The second reaction then transfers the HC C-terminal Asp to 
a C-6 hydroxyl group of an internal GlcNAc residue in HA [25]. The HA-HC complex is utilized for matrix substrates 
while the TSG-6 can be reutilized for another HC transfer reaction. The CS-A chain of the modified II is degraded by 
an unknown mechanism (dashed line) that liberates bikunin, which can then inhibit metalloproteases. 
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kunin-HC1 or bikunin-HC2 [26]. During the inflammatory process, bikunin and the single HC linked 
to CS-A are cleaved by an unknown mechanism to produce free bikunin and HC. TSG-6 is recycled 
to its free state when it acts as a cofactor and catalyst to transfer HC to produce a covalent HC-HA 
complex, also called serum-derived HA-associated protein (SHAP) [27]. The HC undergoes a Mg2+- or 
Mn2+-dependent transesterification reaction between TSG-6 and a GlcUA of HA [25]. The end result 
is that as the HCs of II are transferred and sequestered by TSG-6 and HA. Bikunin, in its monomeric 
form, is the protease inhibitor neutralizing plasmin-induced metalloprotease activity [26]. 
It is the plasmin-induced metalloprotease activities involving leukocyte recruitment and the re-
lease of inflammatory cytokines (TNF-, IL-1, IL-17, LPS, TGF-β, and PGE2) that cause the red and 
swollen features of inflamed tissues. In the case of ovulation, a condition that mimics inflammation, 
cumulus cell ECM remodeling is dependent on TSG-6 and II or PI activities to expand HA-rich 
matrix assembly [28]. PI is an ortholog of II containing just one HC (HC3) connected to bikunin 
via CS-A [29]. The model for TSG-6 interaction with PI is similar to the II-TSG-6 model, in which 
TSG-6 acts a catalyst to transfer HC3 to HA [20]. 
The HA-binding groove of TSG-6 is the best characterized of any of the HA-binding receptors. 
The amino acids essential for HA binding were first identified by site-directed mutagenesis [30] and 
then confirmed by nuclear magnetic resonance (NMR) spectroscopy [7]. Key contact residues in the 
HA-binding groove are Lys11, Tyr12, Tyr59, Phe70, Tyr78, and Arg81. Due to the high content of aro-
matic residues, it is likely that the hydrophobic face of pyranoside rings in HA stack onto the aro-
matic side chains of the amino acids that form two hydrophobic pockets. In addition, Cys47, Val57, 
Ile61, Cys68, and Trp88 are also likely candidates to interact closely with an HA chain. Computer 
modeling of the binding pocket reveals that five sugar rings of HA are required to fill the binding 
groove and that the hydrophobic pockets accommodate the acetamido side chain of GlcNAc [7]. 
Other cellular HA receptors and HA-binding proteins with Link domains also fit this model with 
some degrees of variation. 
2.2 TSG-6 and Heparin 
An increase in plasmin activity is associated with ECM reorganization during inflammation, such 
as occurs in rheumatoid arthritis [31], multiple sclerosis [32], bacterial infection [33], tumorigenesis/
angiogenesis [34], and even follicle rupture during ovulation [35]. Plasmin activity induces the liber-
ation of inflammatory cytokines, as well as activating matrix metalloproteases. TSG-6 is one of sev-
eral molecules that regulate the antiplasmin activity or chondroprotective responses, through II and 
PI, to prevent inflammation-mediated damage to the host. HP, in addition to the more heteroge-
neous HS, also binds TSG-6 and II and is a regulator of serine proteases through its inhibitory ac-
tivity. Using mutagenesis and NMR spectroscopy, Mahoney et al. discovered that HP binds to TSG-6 
at a distinct site from HA [36]. The amino acids involved are Lys20, Lys34, Lys41, and Lys54. Although 
HP does not affect HA-TSG-6 binding, HA and HP cannot both bind to TSG-6 at the same time, in-
dicating that when bound to either GAG, TSG-6 is locked into a conformation that precludes bind-
ing to the other GAG. In addition, HP is a strong competitor for CS-A binding, suggesting that CS-A 
and HP bind at the same site. HP-TSG-6 binding was most optimal at pH 6 and binding affinities 
dropped when the pH shifted in either direction [36]. A lower pH reflects the conditions at sites of in-
flammation, indicating that HP-TSG-6 complexes could have increased antiplasmin activity. In con-
trast, pH changes had no effect on HA-TSG-6 binding. It is not clear how both HA and HP modulate 
the antiplasmin activity of TSG-6, but the current model requires dimerization of TSG-6 [36]. To fur-
ther potentiate the antiplasmin activity of bikunin, two TSG-6 proteins may dimerize when bound 
to a single HP or HS chain (much like a sandwich) and the TSG-6 dimers are able to bind to bikunin. 
This binding may change the orientation of the Kunitz domains of bikunin making them more acces-
sible, thus increasing their antiplasmin activity [36]. 
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To make this story a bit more complex, but perhaps at the same time more reasonable, TSG-6 also 
interacts with TSP1. TSP1 directly inhibits T-cell mediated T-cell activation [37] and dendritic cell ac-
tivation [38], but promotes neutrophil oxidative burst responses [39]. TSP1 is one of many factors in-
volved in early wound repair and mice lacking an effective TSP1 response are delayed in wound 
healing [40]. The N-terminal module of TSP1 is related to the TSG-6-binding pentraxin family of pro-
teins and binds TSG-6 in a divalent cation-dependent manner. The N-terminal module of TSP1 also 
binds HP and is an effective inhibitor of the TSP1 interaction with TSG-6. TSP1 and HA do not bind 
with each other but both bind to TSG-6 at distinct sites. Furthermore, in the absence of HA, TSP1 en-
hances the interaction of TSG-6 with II, resulting in an increased degradation of II. In summary, a 
trimolecular complex consisting of TSP1-HA-TSG-6 acts upon II to give rise to HA-HC complexes 
for ECM remodeling. The presence of HP or HS may negatively regulate this activity [13]. Overall, 
both HA and HP or HS proteoglycans enhance the antiplasmin activities of TSG-6 and concomitant 
effectors during inflammation. 
3 Receptor for Hyaluronic Acid Mediated Motility 
Receptor for hyaluronic acid mediated motility (RHAMM) is present as both a plasma membrane 
GPI-anchored HA receptor and an intracellular HA-binding protein lacking both transmembrane 
and cytoplasmic signal sequences [41]. Consequently, it is also called intracellular hyaluronic acid-
binding protein (IHABP) or CD168. RHAMM was first identified, with the use of anti-RHAMM an-
tibodies, in murine 3T3 cells as a group of HA-binding proteins with molecular masses of 56, 66, 
and 70 kDa [42, 43]. Following this initial discovery, the masses reported for RHAMM have been 
quite variable, ranging from 58 kDa on human B cells [44] to 120 kDa in fibroblasts from src null 
mice [45], based on immunoreactivity against anti-RHAMM antibodies. The wide variety of molecu-
lar masses could be due to proteolysis, different glycosylation states of the receptor [46], or the pres-
ence of splice variants [47]. The full-length human RHAMM, which is about 85% homologous to mu-
rine RHAMM, is identified as a 725-amino acid protein that migrates at ~84 kDa by sodium dodecyi 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
RHAMM is the founding member of hyaladherins (HA-binding proteins) that contain the basic 
B-X7-B motif, in which any seven amino acids are flanked by two basic amino acids, either lysine or 
arginine. RHAMM contains two of these motifs near the C-terminus that mediate high-affinity pro-
tein binding to HA (Kd = 10–8 M) [43, 48]. Mutagenesis of any basic residue flanking the B-X7-B motifs 
led to a sharp decrease in HA binding [49]. Multidimensional NMR analysis of domains containing 
the B-X7-B HA-binding motifs reveals that it is a helix-loop-helix with a coiled-coil tertiary structure, 
which is very different than the architecture of the Link domains found in most other HA-binding 
proteins [5, 50]. RHAMM is a predominantly helical protein containing more basic residues than any 
of the other hyaladherins. Theoretically, the net positive charge of the protein could allow it to bind 
to any GAG due to the high negative charge densities of sulfates of the CS and HS families. How-
ever, none of the CS family members bind to RHAMM. Other than HA, only HP binds to RHAMM 
and competes with HA at the same binding sites. In ras-transformed cells, HP induces cell locomo-
tion in a dose-dependent manner. Biotinylated HP specifically binds to GST-RHAMM and deletion 
of the two B-X7-B motifs negates HP binding [49]. In contrast, other groups dispute the claim that HP 
binds to RHAMM, although all agree that HA binds to RHAMM with high affinity [51, 52]. It is still 
unclear if HP specifically binds to RHAMM because different experimental methodologies and GAG 
sources were employed for determining HP-RHAMM binding, and few follow-up studies have ap-
peared after the HP-RHAMM “controversy” between 1994 and 1998. 
Expression of RHAMM is widespread in a variety of cell types including smooth muscles cells 
[53, 54], and endothelial cells [55]. In addition, overexpression of full-length RHAMM and some of 
its splice variants are found in cancers of the hematopoietic system [56, 57], breast [58, 59], pancreas 
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[60], brain [61], and the lower GI tract [62]. RHAMM is primarily located in the cytoplasm within 
cells, hence the alternative name IHABP, but depending on cell type, it can also be expressed on the 
cell surface where it interacts with focal adhesion sites [63]. 
In the cytoplasm, RHAMM binds intracellular HA and localizes to both microtubules [54] and 
centrosomes, and participates in the maintenance of spindle pole integrity. The function of intracel-
lular HA is unknown, but it is thought to be important during cytokinesis and for cellular move-
ment; how HA functions in these capacities is not clear. Most hypotheses for functions of intracellu-
lar HA point to the hyaladherin (HA binding) activity of RHAMM and thus a role for intracellular 
RHAMM-HA interactions. There is still considerable debate on the source of intracellular HA since 
the three human (and other mammalian) isozymes of HA synthase (HAS) are plasma membrane en-
zymes whose only characterized activity is the extrusion of HA into the ECM [64]. Previous reports 
suggest that intracellular HA is a diffuse network of cable-connecting vesicles, which becomes more 
pronounced with serum stimulation or during mitosis at the G2/M phase [65]. In keratinocytes, ex-
tracellular HA is internalized in a novel endocytic pathway involving CD44 that is independent of 
clathrin-coated pits [66]. It is known that some, but not all internalized, HA is catabolized down to 
monosaccharides and simple organic molecules. The proposed HA-rich, nonacidic vesicles (hyaluro-
nasomes), which would also contain hyaluronidases, are specialized structures that may, theoreti-
cally, be a source of intracellular HA that interact with microtubules and motor proteins to facilitate 
cytokinesis [54, 67]. Despite several similar models in the literature, the hyaluronasome is still a hy-
pothetical structure that has not been biochemically identified, isolated, or characterized. 
RHAMM is a linker protein connecting microtubules via its N-terminus [68] and HA cables via 
its C-terminus [49]. More specifically, the C-terminus of RHAMM also contains a leucine zipper do-
main, essential for binding with dynein- and kinesin-like protein 2 (TPX2), which partially overlaps 
the HA-binding motifs [69]. RHAMM binds directly to TPX2 in a cell cycle-dependent manner, is es-
sential for spindle pole assembly and maintenance throughout the cell cycle, and is required for cell 
progression through G2 of mitosis [70]. The RHAMM interaction with microtubule motors may ex-
plain the role of HA in mitotic regulation and why increased RHAMM expression might enhance the 
oncogenic properties of cells, which is common in several cancer types including multiple myeloma 
[69], breast [59], stomach [71], and endometrial [72]. 
Multiple studies over the last several decades provide a connection between cell motility and HA 
[73–77]. One such study, comparing metastases and primary tumor staining, found that RHAMM 
expression was significantly higher in the metastatic cells. Presentation of RHAMM on the cell sur-
face, where it can interact with external HA, can regulate signaling downstream of ras through ERK, 
the extracellular signal-regulated protein kinase [59] and through Src kinases [45]. Treatment of cells 
with nanogram amounts of HA promoted changes in downstream events such as phosphorylation 
and dephosphorylation of focal adhesion kinase, pp125FAK. This rapid and transient phosphoryla-
tion was regulated in part by RHAMM signal transduction via MAP kinases ERK-1/2 [63, 78]. The 
interaction of ERK and RHAMM stimulates RHAMM binding to cytoskeletal elements that induce 
cellular locomotion [68, 79]. 
The human gene encoding RHAMM is located on chromosome 5q33.2 and contains 18 exons, 
which therefore makes it a likely candidate for alternative splicing [80]. Likewise, the mouse gene 
contains 14 exons and Western analyses of fibroblast cell lysates revealed two bands, a major 70 kDa 
band and a minor larger 73 kDa band encoding exon 4 [41]. An analysis of both breast and cervical 
cancers versus normal tissue revealed the expression of RHAMM splice variants lacking sequences 
encoded by only exon 4, only exon 13, and both exons 4 and 13, suggesting that increased expression 
of RHAMM-like splice variants contribute to an oncogenic phenotype [51, 68]. B cells and plasma 
cells taken from multiple myeloma patients showed two deletion splice variants of RHAMM lack-
ing 48 (RHAMM–48) or 147 DNA base pairs (RHAMM–147), which were expressed in the cancerous 
cells but not in normal or resting B cells [47]. Increased expression of both the full-length and variant 
RHAMM proteins alters normal intracellular signaling pathways, inducing the oncogenic phenotype. 
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4 CD44 
Human CD44, first known as a lymphocyte homing receptor, is a C-type lectin plasma membrane 
receptor that binds to HA and other ECM components, and plays major roles in cytokinesis, endocy-
tosis, phagocytosis, cell signaling, and ligand intemalization. The common or standard CD44 recep-
tor is encoded by exons 1-5, 16–18, and 20, which together produce an ~80 kDa protein. Exons 6–15 
are highly variable exons, commonly named v1–10, whose multiple combinations produce many 
CD44 variants that contribute to its wide array of receptor activities [81]. For example, CD44v6 ex-
presses exon 6 of the variable group, which is really exon 11 if counting from exon 1. 
4.1 CD44 Interactions with HA 
CD44 binds HA via the Link domain encoded by exon 2. This Link domain, which is well con-
served and similar to the Link domains found in other hyaladherins, is ~100 amino acids long, has 
two antiparallel β-sheets crossed over by two -helices, and is held together by two disulfide bridges 
[82]. The receptor on resting leukocytes does not bind HA until it is “activated” by proinflamma-
tory cytokines, which results in the modification of the N-glycans on CD44 [83]. It is thought that tu-
mor necrosis factor-alpha (TNF-) induces sialidase activity to remove sialic acid from the N-glycans, 
which then allows HA-binding to the receptor [84]. The critical residues involved with HA binding 
include Arg41, Tyr42, Arg78, Tyr79, along with the other necessary residues, which are Lys38, Lys68, 
Asn100, Asn101, and Tyr105 [82]. 
4.2 CD44 Interactions with CS 
The CD44 Link domain interacts with the CS family of GAGs. In a competition assay, versican bind-
ing to CD44 was inhibited by HA, Chon, CS-A, CS-B, CS-C, CS-D, and CS-E, but not by HS or KS. In a 
complementary biochemical assay, soluble CD44 also directly bound all these immobilized GAGs with 
the exception of KS and HS [85]. In a rolling cell experiment, murine leukocytes expressing CD44 ini-
tially bound and rolled on capillary tubes coated with CSs at physiological flow rates. The rolling ac-
tion of these cells was abrogated when either the cells were treated with anti-CD44 antibodies or the 
tubes were treated with chrondroitinase ABC, but not hyaluronidase [86]. In a more relevant physio-
logical context, one of the major proteoglycans, Serglycin, is a ligand for CD44. Serglycin (Mr ~17,600; 
previously known as gp600) is secreted by hematopoietic cells and contains CS-A and CS-C chains at-
tached to a centrally located Ser-Gly repeat [87]. Serglycin plays a role in the packaging and inactiva-
tion of some of the proteases in granules of neutraphil granulocytes [88]. Granzyme B, a perforin com-
ponent that can disrupt cell membranes, is packaged in part by Serglycin in the maturing granule of 
cytotoxic T-cells [89–91]. Serglycin is secreted primarily by lymphocytes, spleenoctyes, and thymocytes 
in small amounts, but its secretion is greatly increased by lipopolysaccharide or concanavalin A [87]. 
Murine T-cells expressing CD44 aggregate in the presence of Serglycin-containing serum. Furthermore, 
purified Serglycin binds to CD44 via its CS-A chain, which increases CDS-dependent release of gran-
zyme B, suggesting that this proteo-glycan may regulate lymphoid cell adherence and activation [92, 
93]. Serglycin-deficient T-cells fail to package granzyme B, but not granzyme A, Fas ligand, and perfo-
rin, although the mRNA levels for all three proteins were not affected and the late-stage apoptosis of 
target cells mediated by these cytotoxic cells was also unaffected. In summary, these studies point out 
that the CS chains of Serglycin bind to the HA-binding region of the Link domain of CD44 and is im-
portant in part for the cytotoxic T-cell response in cell-mediated apoptosis and cell rolling. 
4.3 CD44 and HA Endocytosis 
CD44 is the most common endocytic receptor for HA and possibly CS at the local tissue level. 
Initial studies of CD44-mediated endocytosis performed in alveolar macrophages and simian virus 
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transformed murine 3T3 fibroblasts suggested that CD44 is the primary endocytic receptor for HA in 
these cells and responsible for its delivery to lysosomes for degradation [94]. The endocytosis of HA 
also facilitates a higher cycling rate of CD44 on the cell surface of chondrocytes, which is blocked by 
anti-CD44 antibodies [95]. Chondrocytes are present in HA-rich environments where the balance of 
synthesis and catabolism are critical to maintain homeostasis of HA quantity and size (since chain 
length affects viscosity). Decreases in the mass of HA will increase its fluidity and could cause ad-
verse cellular signaling events and, possibly, inflammation (e.g., in arthritis). Once CD44 binds HA, 
the complex is internalized followed by dissociation in an early endosome, most likely the recycling 
syntaxin13 and GTPase Rab11/25-rich endosome that promotes surface expression of ligand-free 
CD44 [96]. This mechanism is regarded as the “slow” recycling pathway with a half-life of about 30 
min. Fast recycling regulated by Rab4 has not been shown to be associated with CD44 recycling. 
The mechanisms of internalization and catabolism of HA are not the same in all tissues. Catabolic 
pathways for HA exist in smooth muscle cells [97], macrophages [94, 98], chondrocytes [99], and 
some cancer cells [100]. Roughly half of all the HA in the human body is localized in the dermal lay-
ers of the skin. Keratinocytes possess a novel, noncoated pit-mediated endocytic pathway for inter-
nalization and catabolism of HA. Epidermal keratinocytes actively produce HA, which has a short 
half-life of ~1.5 days, indicating that the skin is one of the most active tissues in the body for the syn-
thesis and degradation of HA [101, 102]. Partially digested chains of high molecular mass HA [66] 
bound to CD44 are internalized, and trafficked to nonacidic, perinuclear vesicles from which the HA 
is eventually sorted to lysozymes and then degraded to monosaccharides by lysosomal hyaluron-
idase and the two exoglycosidases: β-N-acetylglucosaminidase and β-glucuronidase. The terminal 
HA-degrading vesicles are devoid of Cathepsin D, normally present in lysosomes, suggesting that 
the HA is delivered to a specialized lysosome [66]. 
The route of internalization in keratinocytes is independent of clathrin-coated pit and caveolin-
mediated mechanisms. Consistent with this, the cytoplasmic domain of CD44 does not contain any 
AP-2 or clathrin consensus-binding motifs, suggesting that internalization is regulated by alterna-
tive mechanisms. Exon 20, the most 3′ exon, encodes the intracellular C-terminal 70 amino acids, 
which contains binding sites for ankyrin and the ezrin/radixin/moesin (ERM) linker proteins of 
the actin-based cytoskeletal network and the intracellular signaling cues for internalization, some 
of which have not been elucidated [103, 104]. CD44 is widely thought to be pivotal for HA-induced 
chemotaxis and movements that require cytoskeletal structures. A study with rat endothelial cells in 
situ showed that CD44 and the ERM proteins colocalize with each other on actin filaments near the 
plasma membrane and this region was also enriched with phosphorylated protein kinase C /β II. 
Induction of actin branching facilitated cellular movements needed for normal wound healing. Ad-
dition of protein kinase C (PKC) inhibitors caused F-actin structures to disassemble and the microdo-
mains containing CD44 and associated proteins to disassociate. The end-result of this PKC inhibition 
was to decrease wound healing [105]. CD44 also contains two Ser phosphorylation sites. Inhibition of 
casein kinase II decreased CD44 association with the actin cytoskeleton, suggesting that CD44 is ac-
tivated in a phosphylation- and dephosphorylation-dependent way during cytoskeletal movement 
[106]. Although increased CD44 expression is thought to promote tumorigenesis, at least one of the 
cytoskeletal proteins belonging to the ERM family of proteins may temper this activity. The NF2 
tumor suppressor gene, which encodes Merlin, induces tumorigenesis in Schwann cells through a 
loss-of-function mutation [107]. In cell culture, overexpression of Merlin prevents CD44 from bind-
ing with HA. Additionally, knocking down the expression of endogenous Merlin in Tr6BC1 Schwan-
noma cells in Rag1 mice or overexpression of a dominant-negative Merlin (missing the first 50 amino 
acids from the N-terminus) results in the promotion of tumor cell growth [108]. 
4.4 CD44 and Phagocytosis 
The HA-binding activity of CD44 is diverse enough to include phagocytosis of apoptotic bod-
ies. Following tissue injury and the influx and resulting apoptosis of polymorphonuclear leukocytes 
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(PMN), clearance mechanisms must exist to remove cellular debris in order for normal healing to oc-
cur. The persistence of injury and the lack of healing in CD44-deficient mice demonstrate how CD44 
contributes to the clearing of apoptotic cells [109]. The precise mechanism for how this occurs is still 
unknown. CD44 also contributes to the phagocytosis of bacteria by PMNs, further supporting the no-
tion that ankyrin attached to CD44 assists in the maturation of phagosomes with the inclusion of lyso-
somal vesicles [110]. Confirming these earlier data, a more definitive study using erythrocytes coated 
with either anti-CD44 or control antibodies of the same isotype measured a 25-fold increase in CD44-
selective phagocytosis by RAW 264.7 macrophages in comparison to controls. The induction of cell sig-
naling molecules such as Syk, Rac1, and PI3-kinase during phagocytosis indicates that CD44 is a com-
petent phagocytic receptor, in addition to its HA endocytosis and cell matrix-binding activities [111]. 
4.5 CD44 Splice Variants 
The most common isoform of CD44 is CD44H (H = hematopoietic), also called CD44s (s = stan-
dard), which is encoded by exons 1–5, 16–18, and 20 with a mass of ~80 kDa. The extracellular do-
main contains a variable region encoded by exons 6–15 (also termed variants 1–10) that can increase 
the mass of CD44 to just above 200 kDa and could theoretically result in thousands of different CD44 
splice variant combinations. The inclusion of exon 19 in place of exon 20 is a special case, in which 
the resulting cytoplasmic domain consists of only three amino acids, forming a “tail-less” recep-
tor variant or CD44st (short-tail). CD44st does not bind or internalize HA efficiently and its expres-
sion varies from 5% to 33% of total CD44 receptors in normal articular chondrocytes. Interestingly, 
CD44st may be a one of several regulators for CD44H, since antisense inhibition of CD44st enhances 
HA binding and internalization by CD44H [112]. Other studies with CD44st indicate that the cyto-
plasmic domain of CD44 is also critical for HA binding, pericellular matrix assembly, and endocyto-
sis of HA [113]. It is not known how CD44st interacts with CD44H, but one possibility is steric inter-
ference through common ECM-binding partners. 
Most CD44 splice variants were discovered, with the use of reverse transcription polymerase 
chain reaction (RT-PCR) or immunohistochemistry in cancer specimens, as markers of metasta-
sis [114, 115]. The predominant hypothesis is that the increased expression of CD44 and its variants 
leads to increased cell motility, survival, and sometimes, proliferation of cancerous cells in many 
types of tissues. Hundreds of studies have explored the involvement of many variants in numerous 
types of cancers, so we will briefly note just a few common CD44 variants and their associated can-
cers. Culty et al. first discovered variants in breast cancer. Their findings indicated that not all of the 
higher mass species of CD44 bind HA and those that did bind HA had differing binding affinities 
[100]. CD44v6 and v9 splice variants are present in numerous malignant cancers. CD44v6 associates 
with phosphylated c-Met/hepatocyte growth factor/scatter factor and stimulates downstream sig-
naling through the MAP kinase pathway, stimulating metastasis in colon cancer cells [116]. CD44v6 
and v9 protein levels, but not mRNA levels, are also increased by osteopontin, a secreted phospho-
protein that regulates both chemotaxis and attachment, in breast cancer cells [117]. CD44v6 expres-
sion is increased in higher grades of malignancy in endometrial cancers, suggesting that this isoform 
is directly involved with stromal invasion of early squamous cervical carcinoma [118]. A large-scale 
study by Liu et al. [119] correlated metastasis of breast, gastric, lymph node, colorectal, and lung can-
cers with CD44v6. 
Most studies have shown positive correlations between increased CD44 variant expression and 
disease. For example, CD44v3-10 is usually more highly expressed than normal in head and neck tu-
mors, breast, ovarian, and general gynecological tumors [120–123]. Some studies indicate that CD44 
variants may curtail the activities of CD44H. A study using SW620 cells, which do not express CD44, 
suggests that in this colon cancer cell model, overexpression of CD44 variants leads to a decrease in 
motility. When both CD44H and other CD44 variants are coexpressed, these variants interfere with 
the normal motility functions of CD44H [124]. Recently, the view is emerging that the pattern of 
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CD44 splice variants appears to be more relevant to disease outcomes than the amount of individual 
CD44 variants. For example, normal lung and nonsmall cell lung carcinoma express CD44 v10, v8–
10, v6–10, v2–10, and v3–10. In lung adenocarcinoma, the expression of v6–10, v2–10, and v3–10 were 
lower, whereas in squamous cell lung carcinoma, the expression of these five variants was either the 
same as normal lung or higher [125]. Certainly, the issues of CD44 splice variant expression patterns 
and the different ligands available for the variant region of CD44 is just beginning to be explored. 
4.6 CD44 Knockout Mice 
Since CD44 has many functions including cell-matrix interactions, internalization of HA, and 
transduction of cellular signaling, one would assume that animals lacking CD44 would be develop-
mentally impaired or severely deformed. It turned out that the CD44 knockout mice show no real 
change in phenotype [126]. Their skeleton, cartilage, and skin dermis are quite normal. In conditional 
knockouts in which a CD44 antisense transgene was controlled by the cytokeratin promoter, animals 
overaccumulated HA within the dermis of the skin and in the cornea of the eye [127]. The results 
suggest that during development in the CD44-KO background, compensatory mechanisms exist to 
take care of local HA turnover and ECM stabilization. These compensatory mechanisms either do 
not exist or are overwhelmed when there is a loss of CD44 in developed cells. It is not known what 
receptors might compensate for loss of CD44, but there are some good candidates. RHAMM could 
be one of them, since it binds HA, promotes cell signaling, and leukocyte migration. In the arthritic 
CD44–/– mouse, signaling through the RHAMM pathway upregulates proinflammatory genes such 
as IL-1B, TNF, and MAP kinase. The paw swelling symptom of collagen-induced arthritis was par-
tially alleviated with anti-RHAMM antibody treatment, suggesting that cell migration and ECM sta-
bilization is mediated by RHAMM in the absence of CD44 [128]. Overall, this indicates that RHAMM 
is a compensatory receptor for CD44, but more research is needed to verify this. 
5 Lymphatic Vascular Endothelial Hyaluronan Receptor 1 
As noted above, the CD44–/– mouse has no apparent phenotype and the lymphatic endothelia 
are quite normal in these mice. Another candidate compensatory receptor in the absence of CD44 
is lymphatic vascular endothelial hyaluronan receptor 1 (LYVE-1), a small HA-binding receptor ex-
pressed at high levels in the lymphatics. LYVE-1 is a type I, single-pass ~60 kDa plasma membrane 
glycoprotein containing 322 amino acids. A Link domain, which comprises the bulk of the receptor 
ectodomain, binds only HA, not CS or HS [129]. The cysteines (Cys) of this Link domain are highly 
conserved, but only three other residues (Lys46, Try87, and Asn109) are conserved in the Link fam-
ily and known to be involved with HA binding. Much of the LYVE-1 Link domain is nonconserved, 
which may explain why this particular Link domain only binds HA and none of the other GAGs. On 
the C-terminal side of the Link domain, there are several tracts of basic amino acids, e.g., RRKK198, 
which may also assist in HA binding. Like CD44, LYVE-1 contains one free Cys in the transmem-
brane region that may function as a dimerization stabilizer during receptor- mediated endocytosis 
[130]. Two common pathways for endocytosis are entered by targeting either to clathrin-coated pits 
utilizing tyrosine-based motifs, e.g., YXXB or NPXY, where X is any amino acid and B is an amino 
acid with a bulky hydrophobic side-group [131], or to caveolae utilizing a hydrophobic motif, e.g., 
YXXXFXF [132]. LYVE-1 does not contain consensus sequences for coated-pit-mediated endocyto-
sis, and caveolin-mediated endocytosis by LYVE-1 has not been reported. It is quite possible that 
LYVE-1-mediated uptake is similar to CD44-mediated endocytosis in that the route of endocytosis is 
unique with a recycling receptor going to a specialized compartment where HA is dissociated from 
the receptor and then delivered to an acidic lysosome-like organelle [66]. However, this unusual en-
docytic mechanism is only proven in keratinocytes and is not known to exist in other cell types. 
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LYVE-1 expression is limited to lymph vessel endothelium, but not blood vascular endothelium, 
with the possible exception of the liver sinusoids [133]. Tissues expressing LYVE-1 include lymph ves-
sel endothelia draining GI, skin, breast, lymph node, and salivary gland tissues [129]. Since LYVE-1 
is restricted to lymphatic endothelia, it has been utilized as a distinct marker for lymphangiogenesis. 
Currently, the mechanisms stimulating and directing lymphangiogenesis are largely unknown. Lym-
phangiogenesis is a similar process to hemangiogenesis, which is the outgrowth of new blood vessels 
into tissues. Current evidence indicates that lymphangiogenesis is mediated by vascular endothelial 
growth factor (VEGF-C) and -D binding to VEGFR3 to expand lymphatic vessel outgrowth. Likewise, 
hemangiogenesis is mediated by VEGF-A binding with VEGFR1 and VEGFR2 to promote blood ves-
sel growth [134]. Lymphangiogenesis occurs naturally in growing tissues and grafted tissues. Like 
hemangiogenesis, lymphangiogenesis facilitates the trafficking of monocytes and leukocytes through-
out the tissue. Increased lymphangiogenesis is highly correlated with the rejection of graft tissue [135] 
and poor outcome due to premalignant breast cancer metastasis [136]. In contrast, decreased lymphan-
giogenesis and increased hemangiogenesis are implicated in the development of malignant cancer in 
which the trafficking of white blood cells is restricted [ 137]. A high probability of metastasis and poor 
outcome is observed if the cancer tissue retains the lymph vessel endothelium, allowing the trafficking 
of cancerous cells to spread to other areas of the body [138–140]. 
It is not clear how LYVE-1 fits into the lymphangiogenesis story besides being a good marker for 
lymph endothelium. The primary route of metastatic malignant cells and part of the circulatory route 
of white blood cells is through the lymphatic system. Like CD44, which is a homing receptor for leu-
kocytes, LYVE-1 may facilitate the binding, rolling, and extravasation of leukocytes by its recogni-
tion of HA. Modeling the Link domain of LYVE-1 onto the CD44 Link crystal structure reveals that 
the LYVE-1 Link domain may have an on/off switching mechanism that works similarly to the N-
glycan modification mechanism on CD44 that regulates HA binding [82]. Indirect evidence of this 
switch is evident since the receptor is functionally “off” when expressed in B-lymphoma and cer-
vical carcinoma cells, but functionally “on” when expressed in 293 or COS cells. Treatment of 293T 
cells expressing LYVE-1 with phorbol 12-myristate 13-acetate increases HA binding to LYVE-1 [141]. 
LYVE-1 may also transport HA across the lymphatic endothelium from the interstitium to the lymph 
in a transcytosis process. This idea is supported by the findings that LYVE-1 is on both the luminal 
and abluminal sides of lymphatic capillaries and that the lymphatic endothelia contains intracyto-
plasmic vesicle clusters that may form stable channels that facilitate this type of transport [130, 142]. 
The specific functional aspects of how LYVE-1, a distinct and interesting marker for the lymph endo-
thelium, uses HA in cellular transport has yet to be discovered. 
6 Hyaluronic Acid Receptor for Endocytosis 
The hyaluronic acid receptor for endocytosis (HARE) is the primary scavenger receptor for sys-
temic HA and CS turnover. The adult human body typically contains about 15 g of HA of which ap-
proximately one-third or 5 g is catabolized daily [143–145]. About 50% of the total HA is located in 
the epidermal layers with the remaining enriched in the bursa of the joints, the vitreous humor of the 
eye and, to varying extents, all other tissues. The catabolism of HA occurs at two levels: local, within 
the immediate areas of a tissue, and systemic, involving transport of HA to distal sites. As previ-
ously discussed, CD44, which is found on many cell types of the body, handles much of the local 
HA turnover. However, in the 1980s, Laurent and coworkers observed that most HA is not broken 
down at the local tissue level, but is rather transported through the lymphatic and vascular systems 
to distal sites to be catabolized in the sinusoidal endothelium of the lymph nodes and liver [145–147]. 
The general route of HA turnover involves local partial cleavage in tissues, possibly by hyaluroni-
dases or mechanical/oxidative degradation in the interstitium. The large HA fragments (probably 
with bound proteoglycans) first perfuse through the lymphatic system, which catabolizes about 85% 
of it, with the remaining amount entering the peripheral circulation via the thoracic duct. This resid-
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ual HA is then internalized and degraded in the liver sinusoids; maintaining steady-state HA blood 
levels at <50 ng/mL. 
HARE was first identified, purified, and characterized from rat liver sinusoidal endothelial cells 
[148, 149]. Using cross-reacting monoclonal antibodies, the HARE protein from human spleen was 
then characterized [150], and soon after, molecular cloning of the rat and human HARE were re-
ported [151, 152]. HARE is expressed as two isoforms; a large 300 kDa (rat) or 315 kDa (human) and 
a smaller proteolytically processed 175 kDa (rat) or 190 kDa (human) form. The smaller rat and hu-
man recombinant HARE isoforms were characterized in stable cell lines by Zhou et al. [151] and Har-
ris et al. [152]. The full-length human isoform was cloned and expressed in 293 cell lines and named 
Stabilin-2 due to its close homology to Stabilin-1, which had no known function at that time [153, 
154]. Subsequently, HARE was also named FEEL-2 [155, 156], by other groups, although in the field 
of glycobiology, it is commonly referred to as HARE as it will be in this chapter. Although earlier re-
ports questioned the legitimacy of the smaller isoform [157], we confirmed that cells expressing the 
human full-length recombinant protein from cDNA always produce both HARE isoforms [154]. 
Human HARE is expressed primarily in the medullary sinuses of lymph nodes, sinusoids of the 
liver, and venous sinuses of the spleen. It has also been reported in mice in specialized tissues such as 
corneal and lens epithelium, mesenchymal cells of heart valves, ependymal cells lining the ventricles 
of the brain, and in prismatic epithelial cells covering the renal papillae [158, 159]. The human gene, lo-
cated on chromosome 12q23.3, is 180.2 kb, contains 69 exons and encodes a 2551 amino acid type I re-
ceptor (Figure 2). The glycoprotein mass by SDS-PAGE, including all glycosylation modifications, is 
315/300 kDa and 190/175 kDa for both rat/human isoforms. The smaller isoform is identical to the 
C-terminal 1416 (human)/1431 (rat) amino acids of the full-length HARE protein. A subset of cellular 
HARE is proteolytically cleaved near or at the plasma membrane, but the protease involved remains 
unidentified, and the proteolytic site does not contain a consensus sequence for any known proteases 
[154]. Both isoforms contain numerous fascilin-like and EGF-like domains in complex Cys-rich areas 
and one Link domain near the plasma membrane domain. The function of either the fascilin- and EGF-
like domains is unknown, although they may interact with extracellular/matrix components during 
adhesion, signaling, or ligand interactions. We recently showed that the HARE Link domain is the pri-
mary HA-binding domain [172, 173]. Since the HARE and TSG-6 Link domains share the greatest de-
gree of homology [7] and bind HA with high affinity, it is reasonable that the Link domain is the pri-
mary HA-binding domain of HARE, responsible for ~90% of the binding activity. 
HA-HARE complex formation is high-affinity [154, 160] and cation-independent [161] and inter-
nalization of complexes proceeds via the clathrin-coated pit pathway [151, 162, 163]. The cytoplas-
mic domain contains three motifs involved in clathrin/AP-2 targeting or intracellular trafficking af-
ter endocytosis (e.g., YSYFRI, FQHF, and NPLY) [174]. Subcellular localization of recombinant rat 
HARE is primarily at the cell surface and in endocytic vesicles, but not lysosomes, suggesting that 
HARE is recycled back to the cell surface [151]. Additionally, cycloheximide treatment of isolated 
rat liver endothelial cells (LEC) revealed that endocytosis of 125I-HA proceeds uninterrupted for 
several hours, and the receptors recycle from endosomes back to the cell surface every ~28 min to 
mediate uptake of additional HA [162]. Both rat and human HARE recycle in a similar fashion; re-
combinant 190 kDa human HARE in stable 293 Flp-In cell lines recycles every ~8.5 min, whereas the 
recombinant 175 kDa rat HARE in stable SK-Hep1 cell lines recycles every ~20 min [151, 152]. The 
differences in receptor recycling times is more likely due to cellular machinery differences rather 
than intrinsic to the receptor itself. 
 
6.1 HARE and GAG Binding 
A primary role for HARE is to bind and endocytose HA, but it also internalizes CS-A, CS-C, CS-
D, CS-E, DS, and Chon [152, 172]. It has also been reported to bind advanced glycation end-products, 
collagen N-terminal propeptides, and Gram-negative and Gram-positive bacteria [155, 156, 163]. HA 
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used in our standard endocytic experiments is radiolabeled with 125I only at the reducing end, which 
keeps virtually all of the HA polymer native and unmodified. To assess binding of free CS, HP, or 
HS chains, LECs were incubated with both the 125I-HA and an unlabeled GAG in competition as-
says. Interference of 125I-HA binding by CS and HP in rat LEC was discovered in the 1980s [162, 164, 
165]. Oynebraten et al. [166] found that rat LECs efficiently endocytosed and degraded labeled Ser-
glycin, the serum proteoglycans rich in CS and HS chains. Serglycin also interfered with HA bind-
ing; further supporting the conclusion that HARE is “promiscuous” and able to recognize many dif-
ferent GAGs [158, 167, 172]. As noted previously, CD44 also binds and internalizes Serglycin, but 
the efficiency of binding and endocytosis by HARE is much greater. Later, when the 190 kDa HARE 
was cloned from human spleen and expressed in 293 Flp-In cells, all of the binding and endocytic as-
says indicated that Chon and all of the CS types competed for the binding of labeled HA to varying 
degrees. Inhibition of HA endocytosis was most pronounced with CS-A, CS-C, and CS-D, but was 
not observed with HP, HS, or KS [152]. The discrepancy in results regarding HP competition in ear-
lier [162] versus recent [152] reports leads us to believe the HP used in earlier experiments may have 
contained other GAG impurities. The broad GAG-binding specificity of HARE, its location in lym-
phatic and liver sinusoids, and its fast recycling activity as a coated-pit mediated endocytic receptor 
strongly argues that HARE is the primary scavenger receptor responsible for the clearance of mul-
tiple GAGs, including HA, rather than LYVE-1, CD44, RHAMM, or any other known HA/GAG re-
ceptor. For example, although LYVE-1 is located in lymphoid endothelium, it is not likely a systemic 
scavenger receptor for HA or CS because its binding affinity for HA is too low to be efficient and its 
endocytic uptake rate is less than half that for HARE. We also discovered that HARE is a clearance 
receptor for HP, and that the HA and HP binding sites are separate and independent [172, 173]. 
6.2 HARE and Development 
HA is a molecule that facilitates cell motility in cancer and development, for example, as seen in the 
HA/CD44/RHAMM studies. Since HARE is a recently discovered HA receptor, studies involving its 
role in development are few. HA and other proteoglycans are the foundation of endocardial develop-
ment, chamber septation, and valve development. These ECM components participate in cell signaling 
cascades and creating space for cell infiltration that is necessary for cellular differentiation as the organ 
develops [168–170]. A study examining the role of fascilin-containing genes expressed in heart devel-
opment shows that Stabilin-1, HARE, β-IgH3, and periostin are regulated both spatially and tempo-
rally as the heart develops [159, 171]. HARE expression is restricted to the postnatal mature valve endo-
thelial cells, an area rich in GAGs. Another preliminary study indicates that HARE expression oscillates 
as the fetal rat liver develops. Using histological methods, HARE expression is present as early as day 
13, maximizes by day 15, disappears by day 17, and then reappears on day 18 (P. H. Weigel, unpub-
lished data). It is not known what regulates this differential gene expression although the production 
and scavenging of HA by hyaladherins in organogenesis is critical for proper development. 
7 Conclusion and Future Directions 
The basic ligand-binding functionalities of the HA/CS receptors are fairly well known. Tissue/
ECM remodeling, organ development, and responses to diseases caused by either intrinsic pathol-
ogies (cancer, arthritis, etc.) or external invaders caused by bacterial or viral infections are more of 
the complex roles that involve the HA/CS receptors. There are considerable redundancies in place to 
handle the maintenance of basic life functions in case one of these receptors fails. This is most evident 
in the CD44 and LYVE-1 knockout mice, which contain no obvious phenotype, although multiple 
functions (especially for CD44) have been attributed to the respective receptor. However, each recep-
tor is necessary for the optimal response in the organism to meet all of the different challenges asso-
ciated with life. One of the future challenges for the HA/CS receptors is the understanding of how 
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the molecular machinery is tied in with physiological responses. Despite the numerous studies on 
the subject of endocytosis, the molecular pathways for receptor internalization, ligand uncoupling, 
gene regulation, and transport are only vaguely understood for these receptors. In addition, it is not 
known how these pathways and molecular mechanisms are altered in cases of cancer or infection. 
Current research is still on the observation stage in which we are dissecting the mechanical parts and 
we have much to learn on how these parts work together. 
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